Implementation issues in tuberculosis/HIV program collaboration and integration: 3 Case studies

Journal of Infectious Diseases

Volumn 196, Issue SUPPL. 1, 2007, Pages

  Friedland, Gerald ^a   Harries, Anthony ^b,c,d   Coetzee, David ^e  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MINISTRY OF HEALTH   (Malawi)

^c FAMILY HEALTH INTERNATIONAL   (United States)

^d LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^e UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

CONFERENCE PAPER; HEALTH CARE DELIVERY; HEALTH PROGRAM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; MALAWI; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; SOUTH AFRICA; TUBERCULOSIS; URBAN RURAL DIFFERENCE; WORLD HEALTH ORGANIZATION;

ADOLESCENT; ADULT; ANTI-RETROVIRAL AGENTS; ANTITUBERCULAR AGENTS; CHILD; COOPERATIVE BEHAVIOR; HIV; HIV INFECTIONS; HUMANS; MANAGEMENT SERVICE ORGANIZATIONS; NATIONAL HEALTH PROGRAMS; PROGRAM EVALUATION; RURAL POPULATION; SOUTH AFRICA; TREATMENT OUTCOME; TUBERCULOSIS; URBAN POPULATION;

EID: 34547640162     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/518664     Document Type: Conference Paper

References (41)

1. World Health Organization (WHO). Interim policy on collaborative TB/HIV activities. WHO/HTM/TB/2004.330; WHO/HTM/HIV/2004.1. Geneva: WHO, 2004.
2. Abdool-Karim S, Abdool-Karim Q, Friedland G, Lalloo U, El Sadr W, on behalf of the START project. Implementing antiretroviral therapy in resource constrained settings: opportunities and challenges in integrating HIV and tuberculosis care. AIDS 2004; 18:975-9.
3. American Thoracic Society Centers for Disease Control and Prevention/Infectious Diseases Society of America. Treatment of tuberculosis. Am J Resp Crit Care Med 2003; 167:603-62.
4. World Health Organization (WHO). Scaling up antiretroviral therapy in resource-limited settings: guidelines for a public health approach. Geneva: WHO, 2006.
5. Pozniak A, Miller R, Lipman M, et al. BHIVA treatment guidelines for tuberculosis (TB)/HIV infection. HIV Med 2005; 6:62-83.
6. National AIDS Commission. National estimates of HIV/AIDS in Malawi. Lilongwe, Malawi: National AIDS Commission, 2003.
7. Kwanjana J, Harries A, Gausi F, Nyangulu D, Salaniponi F. HIV-seroprevalence in patients with tuberculosis in Malawi. Malawi Medical Journal 2001; 13:7-10.
8. Salaniponi F, Harries A, Nyirenda T, et al. TB research: putting research into policy and practice. The experience of the Malawi National Tuberculosis Control Programme. WHO/CDS/CPC/TB/99.268. Geneva: Communicable Diseases Cluster of the World Health Organization, 1999.
9. Ministry of Health and Population. Manual of the National Tuberculosis Control Programme of Malawi. 5th ed. Lilongwe, Malawi: Ministry of Health and Population, 2002.
10. Nyirenda T, Harries A, Gausi F, et al. Auditing the new decentralised oral treatment regimens in Malawi. Int J Tuberc Lung Dis 2004; 8:1089-94.
11. World Health Organization (WHO), Joint United Nations Programme on HIV/AIDS (UNAIDS). WHO/UNAIDS secretariat recommendations on the use of cotrimoxazole prophylaxis in adults and children living with HIV/AIDS in Africa. Geneva: WHO/UNAIDS, 2000.
12. Zachariah R, Teck R, Ascurra O, et al. Can we get more HIV-positive tuberculosis patients on antiretroviral treatment in a rural district of Malawi? Int J Tuberc Lung Dis 2005; 9:238-47.
13. Mwaungulu F, Floyd S, Crampin A, et al. Cotrimoxazole prophylaxis reduces mortality in human immunodeficiency virus-positive tuberculosis patients in Karonga district, Malawi. Bull World Health Organ 2004; 82:354-63.
14. Boeree M, Sauvageot D, Banda H, Harries A, Zijlstra E. Efficacy and safety of two dosages of cotrimoxazole as preventive treatment for HIV-infected Malawian adults with new smear-positive tuberculosis. Trop Med Int Health 2005; 10:723-33.
15. Chimzizi R, Harries A, Gausi F, et al. Report of a country-wide survey of HIV/AIDS services in Malawi for the year 2004. National TB Programme, HIV Unit, National AIDS Commission, and Centers for Disease Control and Prevention, Malawi. Lilongwe: Ministry of Health, May 2005.
16. Mermin J, Lule J, Ekwaru P, et al. Effect of cotrimoxazole prophylaxis on morbidity, mortality, CD4-cell count, and viral load in HIV infection in rural Uganda. Lancet 2004; 364:1428-34.
17. Chintu C, Bhat G, Walker A, et al. Co-trimoxazole as prophylaxis against opportunistic infections in HIV-infected Zambian children (CHAP): a double-blind randomised placebo-controlled trial. Lancet 2004; 364:1865-71.
18. Harries A, Nyangulu D, Hargreaves N, Kaluwa O, Salaniponi F. Preventing antiretroviral anarchy in sub-Saharan Africa. Lancet 2001; 358:410-4.
19. Malawi Ministry of Health. Treatment of AIDS: guidelines for the use of antiretroviral therapy in Malawi Vol. 1st ed. Lilongwe, Malawi: Ministry of Health, 2003.
20. Harries A, Gomani P, Teck R, et al. Monitoring the response to antiretroviral therapy in resource-poor settings: the Malawi model. Trans Roy Soc Trop Med Hyg 2004; 98:695-701.
21. Mukherjee J. Basing treatment on rights rather than ability to pay: 3 by 5. Lancet 2004; 363:1071-2.
22. Laurent C, Kouanfack C, Koulla-Shiro S, et al. Effectiveness and safety of a generic fixed dose combination of nevirapine, stavudine, and lamivudine in HIV-1-infected adults in Cameroon: open-label multicentre trial. Lancet 2003; 362:2083-8.
23. Libamba E, Makombe S, Harries A, et al. Scaling up antiretroviral therapy in Africa: learning from tuberculosis control programmes - the case of Malawi. Int J Tuberc Lung Dis 2005; 9:1062-71.
24. Gandhi N, Moll A, Pawinski R, Jack C, Lalloo U, Friedland G. Initiating and providing antiretroviral therapy for TB/HIV coinfected patients in a rural tuberculosis directly observed therapy program in South Africa: the Sizonqoba Study [abstract TuPe7.1C24]. In: Program and abstracts of the 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment (Rio de Janeiro). Geneva: International AIDS Society, 2005.
25. World Health Organization (WHO). Treatment of tuberculosis: guidelines for national programmes. 3rd ed. WHO/CDS/TB/2003.313. Geneva: WHO, 2003.
26. World Health Organization (WHO). Global report on tuberculosis control. WHO/CDS/2005.295. Geneva: WHO, 2005.
27. World Health Organization (WHO). Global tuberculosis control, country profile South Africa. Geneva: WHO, 2004.
28. Wilkinson D, Davies G. The increasing burden of tuberculosis in rural South Africa - impact of the HIV epidemic. S Afr Med J 1997; 87:447-50.
29. Department of Health, South Africa. Department of Health operational plan for comprehensive HIV and AIDS care, management and treatment for South Africa. Pretoria: Department of Health, 2003.
30. Stewart R, Loveday M. The Operational Plan: implementation of the antiretroviral therapy component. In: Ijumba P, Barron P, eds: South African health review 2005. Durban: Health Systems Trust, 2005.
31. Aaron L, Saadoun D, Calatroni L, et al. Tuberculosis in HIV-infected patients: a comprehensive review. Clin Microbiol Infect 2004; 10:388-98.
32. Coetzee D, Hildebrand K, Goemere E, Matthys F, Boelaert M. Integrating tuberculosis and HIV care in the primary care setting in South Africa. Trop Med Int Health 2004; 9:SA11-5.
33. Boulle A, Zweigenthal V, Hildebrand K, Coetzee D. Incidence of tuberculosis pre and post the introduction of ART in a setting of high-HIV co-morbidity. In: Program and abstracts of the XV International AIDS Conference (Bangkok). Geneva: International AIDS Society, 2004.
34. Jack C, Lalloo U, Karim Q, et al. A pilot study of once daily antiretroviral therapy integrated with TB DOT: in a resource limited setting. JAIDS 2004; 36:929-34.
35. Centre for the AIDS Programme of Research in South Africa (CAPRISA); Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH); University of KwaZulu Natal. START: starting tuberculosis and anti-retroviral therapy, a randomized controlled trial to assess the effect of integrated tuberculosis and HIV care on the incidence of AIDS-defining conditions and mortality in participants co-infected with tuberculosis and HIV. Bethesda, MD: NIH, 2004.
36. Ministry of Health and Population Pretoria. The South African Tuberculosis Control Programme practical guidelines, 4th edition. Available at: http://www.doh.gov.za/tb/. Accessed 1 June 2007.
37. Friedland G, Khoo S, Jack C, Lalloo U. Administration of efavirenz (600 mg/day) with rifampicin results in highly variable levels but excellent clinical outcomes in patients treated for tuberculosis and HIV. J Antimicrob Chemother 2006; 58:1299-302.
38. Gandhi N, Moll A, Pawinski R, Zeller K, Lalloo J, Friedland G. Favorable outcomes of the integration of TB and HIV treatment in rural South Africa: the Sizonq'oba study [abstract MOPE0181]. In: Program and abstracts of the XVI International AIDS Conference (Toronto, Canada). Geneva: International AIDS Society, 2006.
39. Gandhi N, Moll A, Sturm AW, et al. Modified extensively drug-resistant tuberculosis (XDR TB) as a cause of death among TB/HIV co-infected patients in a rural area in South Africa. Lancet 2006; 368:1575-80.
40. Wells CD, Cegielski JP, Nelson LJ, et al. HIV infection and multidrug-resistant tuberculosis - the perfect storm. J Infect Dis 2007; 196(Suppl 1):S86-107 (in this supplement).
41. Bock NN, Jensen PA, Miller B, Nardell E. Tuberculosis infection control in resource-limited settings in the era of expanding HIV care and treatment. J Infect Dis 2007; 196(Suppl 1):S108-13 (in this supplement).